COVID-19 SARS-CoV-2 Screening Protocol

NCT04740320 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2024-08-13

Study results available
· View outcomes & findings →

Summary

The aim of this screening protocol is to assess volunteers for their potential eligibility to participate in a dose finding human experimental infection study in healthy subjects using a GMP-produced SARS-CoV-2 wild type strain

Conditions

  • Covid19

Sponsors & Collaborators

  • Hvivo

    collaborator INDUSTRY
  • Imperial College London

    lead OTHER

Principal Investigators

  • Chris Chiu · Imperial College London

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-15
Primary Completion
2021-06-23
Completion
2021-07-09

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04740320 on ClinicalTrials.gov